Sharemaestro Newsreel

Evotec and Odyssey Therapeutics team up to accelerate AI-driven drug discovery for autoimmune diseases

Evotec SE and Odyssey Therapeutics have formed a strategic R&D collaboration to accelerate AI-driven drug discovery for autoimmune and inflammatory diseases. The partnership will combine Evotec’s data-driven drug discovery platform, AI-enabled technologies, and screening capabilities with Odyssey’s expertise in disease biology to identify and …

Tilray Brands Expects to Hit a Major Milestone for the Current Fiscal Year: $1 Billion in Annual Revenue. Here's How it Plans to Get There

Tilray Brands (NASDAQ: TLRY) recently posted record earnings numbers and is focused on even more growth ahead. For the coming fiscal year, it anticipates full-year revenue will exceed $1 billion. It would be a huge milestone for the company, whose growth prospects have been …

Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline

Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting …

5 Stocks With Recent Price Strength to Tap August Rally

U.S. stock markets returned to a northward journey after a mixed June and July. In the first week of August, the Dow, the S&P 500 and the Nasdaq Composite rallied 3%, 3.6% and 5.2%, respectively. All three major stock indexes posted their best weekly …

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported its Q2 2026 financial results, including $20.7 million in revenue from its Viatris collaboration and a GAAP net loss of $5.9 million, with $387.7 million in cash and marketable securities. The company highlighted strong YUPELRI performance, a pending acquisition by Zymeworks, …

Harrow earnings up next: Can ophthalmic firm stage Q2 comeback?

Harrow Health Inc. is set to report its second-quarter earnings, with analysts expecting a significant rebound in revenue and a narrowed loss after a disappointing first quarter. Despite unanimous "buy" ratings from analysts and a substantial implied upside, investors are keenly watching if the …

Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside

Aquestive Therapeutics Inc (AQST) is preparing to release its Q2 2026 earnings on August 11, 2026, with revenue expected at $11.42 million and earnings at $-0.12 per share. While analysts predict a significant upside of 125.61% based on average price targets, GuruFocus's GF Value …

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film

Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. …

Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00

Canaccord Genuity Group has lowered its price target for ANI Pharmaceuticals (NASDAQ:ANIP) to $90.00 from $91.00, while maintaining a "hold" rating. This implies a potential upside of 15% from the previous closing price. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of …

Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector …

1 Healthcare Stock Worth Your Attention and 2 We Ignore

1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over …

Alvotech to Report Financial Results for H1 2026

Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company, announced it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A on Thursday, …

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)

Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials

Aquestive Therapeutics has released supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program. A resubmission human factors study showed fewer use issues compared to the original NDA study, with a median open time reduced to 3 seconds. A …

Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning

Amphastar Pharmaceuticals (AMPH) reported strong Q2 2026 revenue of $183.9M, a 5% year-over-year increase, significantly boosted by a $100M payment from a $175M BAQSIMI milestone. However, the company faces potential increased remediation costs and slowed batch releases due to an FDA warning letter issued …

Alvotech Schedules Live Q&A After Its H1 2026 Results Release

Alvotech (NASDAQ: ALVO) will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A session on Thursday, August 20, 2026, at 08:00 ET. …

BrewDog campaign will distribute 20,000 chilled Punk IPA cans

Tilray's Scottish craft beer subsidiary, BrewDog, has launched its "Park IPA" campaign in London. The initiative rebrands its flagship Punk IPA as Park IPA for August, aiming to align the beer with London's summer park-drinking culture. The campaign includes distributing 20,000 chilled cans via …

H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook

H.C. Wainwright has reduced its price target for Emergent BioSolutions (NYSE:EBS) to $10 from $12, while maintaining a Buy rating, due to a lowered full-year 2026 revenue guidance. The company's NARCAN sales have declined significantly due to new competition in the naloxone market, despite …

Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026

Aquestive announced positive human factors and pharmacokinetic (PK) results for Anaphylm, indicating significant improvements in usability and comparable drug delivery. These results support the planned New Drug Application (NDA) resubmission in Q3 2026 for the epinephrine treatment. The study showed reduced errors in self-administration …

BTAI Q2'26 Earnings: EPS estimate is (0.44) USD

BioXcel Therapeutics, Inc. (BTAI) is expected to announce its Q2'26 earnings on August 11, with an estimated revenue of 484.63 thousand USD and an EPS of (0.44) USD. The article provides a table of historical and estimated revenue and EPS figures, along with surprise …

Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS

Tilray to cease brewing at Terrapin site in US

Tilray Brands will stop brewing beer at its Terrapin facility in Athens, Georgia, moving production to other breweries within its network as part of a broader optimization strategy. The taproom, warehouse, and repack operations in Athens will remain open, and Terrapin will continue as …

TEVA (TEVA) director Tal Zvi Zaks sells 17 shares, retains 73,247

Tal Zvi Zaks, a director at TEVA PHARMACEUTICAL INDUSTRIES LTD, sold 17 Ordinary Shares at $34.8655 per share on August 5, 2026, in an open market or private transaction. Following this sale, Zaks directly holds 73,247 Ordinary Shares. The transaction was not executed under …

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical company specializing in the production of proprietary enzymes and devices. …

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Exploring a 16.52% Upside Potential

Teva Pharmaceutical Industries (TEVA) shows a potential upside of 16.52% according to analysts, with an average price target of $41.20. Despite a slight revenue decline, the company boasts strong operational efficiency and a diverse product portfolio in generic and specialty medicines. While it doesn't …

Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS

Renaissance Technologies LLC reduced its stake in Xeris Biopharma Holdings, Inc. by 26.9% in the first quarter, selling 166,800 shares but still owning 452,860 shares valued at approximately $2.63 million. Institutional investors collectively hold 42.75% of XERS, and analysts maintain a "Moderate Buy" consensus …

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit, filed on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleges that the company made false …

Liquidia Corporation $LQDA Stock Holdings Lifted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company significantly increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 63.3% in the first quarter, now holding 58,265 shares valued at $2.2 million. Institutional investors collectively own 64.54% of Liquidia. Analysts maintain a "Moderate Buy" rating with an average price …

Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) during the first quarter, selling 1.76 million shares and retaining 1.83 million, now valued at $2.55 million. Despite this, Akebia reported stronger-than-expected quarterly revenues of $49.13 million and a smaller loss per share …

Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback

Viatris Inc. recently reported higher Q2 and year-to-date revenues, returned to net income, raised its full-year 2026 revenue guidance to US$14.75 billion, and completed a US$1.15 billion share repurchase program. Despite these positive developments, including a new FDA-approved contraceptive patch and reaffirmed dividend, the …

Zoetis (ZTS) Is Down 5.8% After Cutting 2026 Outlook And Overhauling Leadership Structure

Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH

Empowered Funds LLC initiated a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by purchasing 11,979 shares valued at approximately $909,000. This comes as Lantheus exceeded quarterly earnings expectations, reporting $1.55 EPS against a $1.30 consensus, though analyst sentiment has softened with several downgrades to …

US Stock Market Today: S&P 500 Futures Climb On Softer Jobs Data And Yields

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The Morning Bull - US Market Morning Update Monday, Aug, 10 2026 US stock futures are pointing higher this morning, with the S&P …

California State Teachers Retirement System Has $2.73 Million Stock Holdings in Liquidia Corporation $LQDA

The California State Teachers Retirement System increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 25% to 72,438 shares, now valued at approximately $2.73 million. Institutional investors collectively own 64.54% of the company, which has received a consensus "Moderate Buy" rating from analysts with an …

Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates